CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: LINC00963 (ImmuneEditome ID:100506190)

1. Gene summary of enriched editing regions for LINC00963

check button Gene summary
Gene informationGene symbol

LINC00963

Gene ID

100506190

GeneSynonymsMetaLnc9
GeneCytomap

9q34.11

GeneTypencRNA
GeneDescription-
GeneModificationdate20230329
UniprotID.
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr9:129491964-129493107:+ENST00000622680.1ENSG00000204054.10LINC00963ncRNA_exonicMIRb,AluSp,AluSx1,MIR3chr9:129491964-129493107:+.alignment
chr9:129502379-129503034:+ENST00000412141.1ENSG00000204054.10LINC00963ncRNA_exonicAluSx,AluYchr9:129502379-129503034:+.alignment
chr9:129502379-129503034:+ENST00000423918.4ENSG00000204054.10LINC00963ncRNA_exonicAluSx,AluYchr9:129502379-129503034:+.alignment
chr9:129502379-129503034:+ENST00000454635.5ENSG00000204054.10LINC00963ncRNA_exonicAluSx,AluYchr9:129502379-129503034:+.alignment
chr9:129502379-129503034:+ENST00000607931.1ENSG00000204054.10LINC00963ncRNA_exonicAluSx,AluYchr9:129502379-129503034:+.alignment
chr9:129502379-129503034:+ENST00000608272.1ENSG00000204054.10LINC00963ncRNA_exonicAluSx,AluYchr9:129502379-129503034:+.alignment
chr9:129502379-129503034:+ENST00000608669.1ENSG00000204054.10LINC00963ncRNA_exonicAluSx,AluYchr9:129502379-129503034:+.alignment
chr9:129502379-129503034:+ENST00000624009.2ENSG00000204054.10LINC00963ncRNA_exonicAluSx,AluYchr9:129502379-129503034:+.alignment
chr9:129504107-129504436:+ENST00000419300.3ENSG00000204054.10LINC00963ncRNA_exonicMER46C,AluSxchr9:129504107-129504436:+.alignment
chr9:129504107-129504436:+ENST00000444184.4ENSG00000204054.10LINC00963ncRNA_exonicMER46C,AluSxchr9:129504107-129504436:+.alignment
chr9:129504107-129504436:+ENST00000454968.4ENSG00000204054.10LINC00963ncRNA_exonicMER46C,AluSxchr9:129504107-129504436:+.alignment
chr9:129505935-129508836:+ENST00000419300.3ENSG00000204054.10LINC00963ncRNA_exonicAluSx,AluSq10,AluJb,L1MD2,AluSz,MER66B,MIR3,AluY,AluYf1,L2cchr9:129505935-129508836:+.alignment
chr9:129505935-129508836:+ENST00000624009.2ENSG00000204054.10LINC00963ncRNA_exonicAluSx,AluSq10,AluJb,L1MD2,AluSz,MER66B,MIR3,AluY,AluYf1,L2cchr9:129505935-129508836:+.alignment
chr9:129509997-129513099:+ENST00000419300.3ENSG00000204054.10LINC00963ncRNA_exonicAluSg,AluSz,MLT1A0,AluJb,MIRb,AluSp,L1MEf,L1ME3Achr9:129509997-129513099:+.alignment


Top

2. Tumor-specific enriched editing regions for LINC00963


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr9:129504107-129504436:+BRCAEER1.8350e-13image
chr9:129505935-129508836:+BRCAEER7.5449e-13image
ENSG00000204054.10,LINC00963BRCAEAG3.9735e-11image
chr9:129505935-129508836:+COADEER2.5389e-03image
chr9:129504107-129504436:+HNSCEER2.2010e-06image
chr9:129505935-129508836:+HNSCEER5.2226e-10image
ENSG00000204054.10,LINC00963HNSCEAG5.7666e-06image
chr9:129504107-129504436:+KIRCEER1.6049e-03image
chr9:129505935-129508836:+KIRCEER1.0352e-02image
ENSG00000204054.10,LINC00963KIRCEAG4.6761e-05image
chr9:129504107-129504436:+KIRPEER1.7443e-02image
chr9:129504107-129504436:+LUADEER8.2600e-14image
chr9:129505935-129508836:+LUADEER8.5756e-13image
ENSG00000204054.10,LINC00963LUADEAG1.3931e-15image
chr9:129504107-129504436:+LUSCEER3.2033e-17image
chr9:129505935-129508836:+LUSCEER2.9683e-10image
ENSG00000204054.10,LINC00963LUSCEAG9.5171e-23image
ENSG00000204054.10,LINC00963PRADEAG3.4131e-02image
chr9:129504107-129504436:+THCAEER4.3901e-09image
chr9:129505935-129508836:+THCAEER7.2807e-11image
chr9:129509997-129513099:+THCAEER2.2079e-02image
ENSG00000204054.10,LINC00963THCAEAG7.8524e-12image
chr9:129505935-129508836:+UCECEER8.0431e-03image
ENSG00000204054.10,LINC00963UCECEAG2.9525e-04image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr9:129505935-129508836:+KIRCPathEER3.9887e-038.9878e-040.1459image
ENSG00000204054.10,LINC00963LUSCPathEAG1.0085e-022.3974e-020.1022image
chr9:129504107-129504436:+LUSCPathEER8.1286e-045.5220e-030.1260image
chr9:129504107-129504436:+THCAPathEER3.0599e-031.7884e-030.1389image
chr9:129504107-129504436:+UCSCliEER2.5787e-022.3299e-03-0.4023image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for LINC00963


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr9:129504107-129504436:+COADEERENSG00000117523,PRRC2C0.22301.1548e-024.9969e-120.4112imageNNPRRC2CEosinophilsGSVA_HALLMARK_DNA_REPAIR
chr9:129504107-129504436:+COADEERENSG00000117523,PRRC2C0.22301.1548e-024.9969e-120.4112imageNNPRRC2CEosinophilsGSVA_HALLMARK_DNA_REPAIR
chr9:129504107-129504436:+COADEERENSG00000117523,PRRC2C0.22301.1548e-024.9969e-120.4112imageNNPRRC2CEosinophilsGSVA_HALLMARK_DNA_REPAIR
chr9:129505935-129508836:+PCPGEERENSG00000154277,UCHL10.45653.8971e-056.7596e-070.4151imageNNUCHL1T_cells_regulatory_(Tregs)GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr9:129505935-129508836:+THYMEERENSG00000110108,TMEM109-0.46363.7705e-051.3537e-06-0.4400imageNNNANeutrophilsGSVA_HALLMARK_BILE_ACID_METABOLISM
chr9:129505935-129508836:+THYMEERENSG00000110442,COMMD90.45255.8915e-053.7682e-060.4229imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR
chr9:129505935-129508836:+THYMEERENSG00000072840,EVC-0.44437.9660e-051.8574e-06-0.4348imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr9:129505935-129508836:+THYMEERENSG00000237976,RP11-126K1.60.43448.5604e-051.0811e-060.4436imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr9:129505935-129508836:+THYMEERENSG00000151413,NUBPL-0.44508.9550e-051.2152e-06-0.4417imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr9:129505935-129508836:+THYMEERENSG00000147164,SNX12-0.43801.2926e-042.0918e-06-0.4328imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr9:129505935-129508836:+THYMEERENSG00000189159,HN10.42941.3647e-045.6775e-060.4158imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr9:129505935-129508836:+THYMEERENSG00000130311,DDA10.42061.6584e-045.4408e-060.4165imageNNDDA1T_cells_regulatory_(Tregs)GSVA_HALLMARK_E2F_TARGETS
chr9:129505935-129508836:+THYMEERENSG00000103037,SETD6-0.42411.8698e-042.7948e-06-0.4280imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR
chr9:129505935-129508836:+PCPGEERENSG00000154277,UCHL10.45653.8971e-056.7596e-070.4151imageNNUCHL1T_cells_regulatory_(Tregs)GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr9:129505935-129508836:+THYMEERENSG00000110108,TMEM109-0.46363.7705e-051.3537e-06-0.4400imageNNNANeutrophilsGSVA_HALLMARK_BILE_ACID_METABOLISM
chr9:129505935-129508836:+THYMEERENSG00000110442,COMMD90.45255.8915e-053.7682e-060.4229imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR
chr9:129505935-129508836:+THYMEERENSG00000072840,EVC-0.44437.9660e-051.8574e-06-0.4348imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UV_RESPONSE_DN
chr9:129505935-129508836:+THYMEERENSG00000237976,RP11-126K1.60.43448.5604e-051.0811e-060.4436imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
chr9:129505935-129508836:+THYMEERENSG00000151413,NUBPL-0.44508.9550e-051.2152e-06-0.4417imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr9:129505935-129508836:+THYMEERENSG00000147164,SNX12-0.43801.2926e-042.0918e-06-0.4328imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr9:129505935-129508836:+THYMEERENSG00000189159,HN10.42941.3647e-045.6775e-060.4158imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr9:129505935-129508836:+THYMEERENSG00000130311,DDA10.42061.6584e-045.4408e-060.4165imageNNDDA1T_cells_regulatory_(Tregs)GSVA_HALLMARK_E2F_TARGETS
chr9:129505935-129508836:+THYMEERENSG00000103037,SETD6-0.42411.8698e-042.7948e-06-0.4280imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR
chr9:129509997-129513099:+OVEERENSG00000204054,LINC00963-0.45582.8122e-091.1579e-11-0.4280imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE

More results



Top

4. Enriched editing regions and immune related splicing for LINC00963


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000204054.10,LINC00963
COADEAGESENSG00000172785.14chr9134978:135030:146101:146158:152033:152078-0.23922.1835e-022.2457e-12-0.4165imageNADAR;BUD13;CPSF6;CSTF2T;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LIN28;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;SAFB2;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;TAF15;TARDBP;TIA1;TIAL1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NAPlasma_cellsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000204054.10,LINC00963
COADEAGESENSG00000103121.4chr1680976116:80976179:80981805:80981877:80997313:80997372-0.25598.7765e-036.0603e-12-0.4090imageNADAR;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LARP7;LIN28;LIN28B;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_PEROXISOME
chr9:129504107-129504436:+
COADEERESENSG00000103121.4chr1680976116:80976179:80981805:80981877:80997313:80997372-0.24161.7877e-024.0761e-12-0.4135imageNNNADendritic_cells_activatedGSVA_HALLMARK_PEROXISOME
chr9:129504107-129504436:+
COADEERIRENSG00000165724.5chr9137586966:137587823:137588658:1375887180.21704.9320e-021.0738e-140.4551imageNNNAEosinophilsGSVA_HALLMARK_UV_RESPONSE_UP
chr9:129505935-129508836:+
GBMEERMEXENSG00000173726.6chr1235113767:235113910:235117581:235117704:235119338:235119406:235119817:2351198990.17881.4172e-026.2143e-070.4524imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MYC_TARGETS_V2
chr9:129505935-129508836:+
PAADEERESENSG00000128335.9chr2236233401:36233455:36236595:36237363:36239440:362395270.39171.3342e-034.8441e-110.4770imageNNAPOL2T_cells_CD4_naiveGSVA_HALLMARK_P53_PATHWAY
chr9:129504107-129504436:+
PAADEERIRENSG00000008853.12chr823004043:23006145:23006727:23007746-0.31021.2452e-021.8041e-07-0.4355imageNNNAMacrophages_M0GSVA_HALLMARK_GLYCOLYSIS
chr9:129505935-129508836:+
PCPGEERESENSG00000151914.13chr656528840:56528925:56529447:56529774:56529973:56530133-0.30932.0755e-021.6398e-05-0.4145imageNNDSTT_cells_CD8GSVA_HALLMARK_NOTCH_SIGNALING
chr9:129505935-129508836:+
THYMEERIRENSG00000204977.5chr1349997018:49997131:49997666:499977630.33451.7622e-022.8950e-060.4568imageNNTRIM13Macrophages_M1GSVA_HALLMARK_PROTEIN_SECRETION
chr9:129505935-129508836:+
THYMEERESENSG00000111731.8chr1222456970:22457161:22458483:22459542:22469708:22469795-0.43105.6762e-041.1779e-06-0.4680imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR

More results



Top

5. Enriched editing regions and immune infiltration for LINC00963


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr9:129505935-129508836:+ACCEERMacrophages_M11.5398e-020.2846image
chr9:129509997-129513099:+ACCEERPlasma_cells3.2592e-020.4048image
ENSG00000204054.10,LINC00963ACCEAGMacrophages_M08.0157e-03-0.3040image
chr9:129504107-129504436:+BLCAEERMacrophages_M11.2970e-030.1625image
chr9:129505935-129508836:+BLCAEERMacrophages_M18.2784e-050.2091image
ENSG00000204054.10,LINC00963BLCAEAGMacrophages_M11.2008e-040.1916image
chr9:129504107-129504436:+BRCAEERDendritic_cells_activated1.1881e-030.0986image
chr9:129505935-129508836:+BRCAEERDendritic_cells_activated8.0424e-040.1032image
chr9:129509997-129513099:+BRCAEERT_cells_regulatory_(Tregs)1.3096e-02-0.1082image
ENSG00000204054.10,LINC00963BRCAEAGDendritic_cells_activated1.1456e-020.0769image
chr9:129504107-129504436:+CESCEERMonocytes1.7221e-02-0.1372image
chr9:129505935-129508836:+CESCEERDendritic_cells_activated2.4303e-040.2161image
chr9:129509997-129513099:+CESCEERMacrophages_M14.6037e-020.2702image
ENSG00000204054.10,LINC00963CESCEAGT_cells_CD4_memory_resting5.9852e-04-0.1964image
chr9:129504107-129504436:+CHOLEERNeutrophils4.8057e-020.3366image
chr9:129505935-129508836:+CHOLEERMacrophages_M21.3113e-02-0.4338image
ENSG00000204054.10,LINC00963CHOLEAGNK_cells_resting2.7934e-02-0.3716image
chr9:129504107-129504436:+COADEEREosinophils5.1229e-030.1731image
chr9:129505935-129508836:+COADEERDendritic_cells_activated1.6331e-02-0.1600image
ENSG00000204054.10,LINC00963COADEAGEosinophils1.9630e-020.1441image
chr9:129504107-129504436:+DLBCEERT_cells_follicular_helper4.3090e-02-0.3064image
chr9:129505935-129508836:+DLBCEERT_cells_regulatory_(Tregs)1.2316e-02-0.4928image
ENSG00000204054.10,LINC00963DLBCEAGT_cells_regulatory_(Tregs)2.4601e-02-0.3385image
chr9:129502379-129503034:+ESCAEERMast_cells_activated3.0303e-020.2076image
chr9:129505935-129508836:+ESCAEERNeutrophils1.3118e-02-0.1982image
chr9:129509997-129513099:+ESCAEERT_cells_CD4_naive1.2118e-040.3842image
chr9:129504107-129504436:+GBMEERT_cells_CD4_memory_resting2.6442e-020.1744image
chr9:129505935-129508836:+GBMEERMacrophages_M24.7967e-020.1618image
chr9:129509997-129513099:+GBMEERNK_cells_activated3.8016e-02-0.1929image
chr9:129504107-129504436:+HNSCEERT_cells_regulatory_(Tregs)1.7329e-03-0.1428image
chr9:129505935-129508836:+HNSCEERT_cells_regulatory_(Tregs)1.7385e-02-0.1151image
ENSG00000204054.10,LINC00963HNSCEAGT_cells_regulatory_(Tregs)1.0697e-04-0.1741image
ENSG00000204054.10,LINC00963KICHEAGT_cells_follicular_helper6.1958e-030.3361image
chr9:129504107-129504436:+KIRCEERT_cells_CD4_memory_activated3.6941e-030.1482image
chr9:129505935-129508836:+KIRCEERT_cells_CD81.4846e-050.2234image
chr9:129509997-129513099:+KIRCEEREosinophils5.3786e-030.2017image
ENSG00000204054.10,LINC00963KIRCEAGT_cells_CD4_memory_activated1.2476e-030.1646image
chr9:129505935-129508836:+KIRPEERT_cells_follicular_helper9.5438e-080.3096image
ENSG00000204054.10,LINC00963KIRPEAGT_cells_CD4_memory_resting3.5786e-03-0.1711image
chr9:129504107-129504436:+LAMLEERT_cells_CD81.6643e-02-0.2321image
ENSG00000204054.10,LINC00963LAMLEAGNK_cells_resting2.6134e-020.2121image
chr9:129504107-129504436:+LGGEERMacrophages_M03.3026e-05-0.1805image
chr9:129505935-129508836:+LGGEERB_cells_memory2.9713e-020.0975image
chr9:129509997-129513099:+LGGEERMast_cells_resting1.0488e-02-0.1227image
ENSG00000204054.10,LINC00963LGGEAGB_cells_memory1.0210e-050.1911image
chr9:129505935-129508836:+LIHCEERMacrophages_M08.1122e-03-0.1380image
ENSG00000204054.10,LINC00963LIHCEAGMacrophages_M07.8139e-03-0.1379image
chr9:129504107-129504436:+LUADEERMast_cells_resting1.4415e-03-0.1413image
chr9:129505935-129508836:+LUADEERT_cells_CD4_memory_activated6.3166e-040.1561image
chr9:129509997-129513099:+LUADEERT_cells_CD4_memory_resting8.4457e-030.2365image
ENSG00000204054.10,LINC00963LUADEAGDendritic_cells_activated7.9604e-040.1482image
chr9:129504107-129504436:+LUSCEERMacrophages_M21.9946e-02-0.1057image
chr9:129505935-129508836:+LUSCEERMast_cells_resting1.0178e-02-0.1206image
chr9:129509997-129513099:+LUSCEERMast_cells_resting2.6954e-020.2386image
ENSG00000204054.10,LINC00963LUSCEAGMacrophages_M27.6302e-04-0.1517image
ENSG00000204054.10,LINC00963MESOEAGNK_cells_activated2.0352e-02-0.2558image
chr9:129491964-129493107:+OVEERMacrophages_M15.8255e-040.7005image
chr9:129502379-129503034:+OVEERNeutrophils9.9227e-030.1824image
chr9:129505935-129508836:+OVEERB_cells_memory3.5508e-020.1246image
ENSG00000204054.10,LINC00963OVEAGB_cells_memory4.1187e-030.1674image
chr9:129504107-129504436:+PAADEERT_cells_CD82.4414e-03-0.2271image
chr9:129505935-129508836:+PAADEERT_cells_CD81.9798e-03-0.2336image
ENSG00000204054.10,LINC00963PAADEAGT_cells_CD87.2789e-03-0.2011image
chr9:129504107-129504436:+PCPGEERT_cells_follicular_helper1.4677e-020.1869image
chr9:129505935-129508836:+PCPGEERT_cells_CD84.1323e-030.2471image
ENSG00000204054.10,LINC00963PCPGEAGT_cells_CD81.2163e-020.1886image
chr9:129504107-129504436:+PRADEERMast_cells_activated8.8464e-04-0.1485image
chr9:129505935-129508836:+PRADEERPlasma_cells2.5003e-03-0.1356image
chr9:129509997-129513099:+PRADEERDendritic_cells_activated3.3743e-020.1234image
ENSG00000204054.10,LINC00963PRADEAGT_cells_CD4_memory_resting1.0471e-040.1728image
chr9:129504107-129504436:+READEERMonocytes5.1238e-030.2865image
chr9:129505935-129508836:+READEERT_cells_follicular_helper2.9149e-02-0.2410image
ENSG00000204054.10,LINC00963READEAGMonocytes7.3822e-030.2732image
chr9:129505935-129508836:+SARCEERMacrophages_M16.0182e-040.2151image
chr9:129509997-129513099:+SARCEEREosinophils6.2027e-040.2548image
ENSG00000204054.10,LINC00963SARCEAGT_cells_CD4_memory_resting2.7039e-020.1379image
chr9:129504107-129504436:+SKCMEERB_cells_memory9.9339e-03-0.1204image
chr9:129505935-129508836:+SKCMEERMast_cells_activated7.5698e-03-0.1272image
ENSG00000204054.10,LINC00963SKCMEAGEosinophils6.1272e-030.1272image
chr9:129491964-129493107:+STADEERT_cells_CD4_memory_activated8.1798e-030.4526image
chr9:129502379-129503034:+STADEERMacrophages_M04.9701e-02-0.1433image
chr9:129505935-129508836:+STADEERT_cells_CD82.3169e-020.1235image
chr9:129509997-129513099:+STADEERT_cells_CD4_memory_resting3.7112e-03-0.2333image
ENSG00000204054.10,LINC00963STADEAGT_cells_regulatory_(Tregs)1.7646e-020.1242image
chr9:129504107-129504436:+TGCTEERNK_cells_activated3.9191e-020.2098image
chr9:129505935-129508836:+TGCTEERT_cells_CD81.3180e-020.2889image
ENSG00000204054.10,LINC00963TGCTEAGNK_cells_activated5.9675e-030.2679image
chr9:129504107-129504436:+THCAEERMacrophages_M26.0313e-04-0.1523image
chr9:129505935-129508836:+THCAEERT_cells_CD4_memory_activated4.8317e-040.1550image
chr9:129509997-129513099:+THCAEERT_cells_CD4_memory_activated8.0920e-030.1384image
ENSG00000204054.10,LINC00963THCAEAGDendritic_cells_resting2.1542e-030.1364image
chr9:129504107-129504436:+THYMEERNeutrophils8.3517e-030.2418image
chr9:129505935-129508836:+THYMEERT_cells_regulatory_(Tregs)3.5030e-040.3333image
ENSG00000204054.10,LINC00963THYMEAGT_cells_regulatory_(Tregs)6.3671e-030.2498image
chr9:129505935-129508836:+UCECEERT_cells_CD4_memory_resting1.0541e-03-0.2528image
chr9:129509997-129513099:+UCECEERNeutrophils3.7016e-030.3920image
ENSG00000204054.10,LINC00963UCECEAGT_cells_CD4_memory_activated1.9734e-020.1771image
chr9:129504107-129504436:+UCSEERPlasma_cells2.5338e-020.3014image
ENSG00000204054.10,LINC00963UCSEAGPlasma_cells1.6658e-020.3216image
chr9:129505935-129508836:+UVMEERMonocytes3.9069e-030.4310image
ENSG00000204054.10,LINC00963UVMEAGDendritic_cells_activated6.0161e-050.4765image


Top

6. Enriched editing regions and immune gene sets for LINC00963


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000204054.10,LINC00963BLCAEAG2.6710e-040.18182.0286e-040.18528.8000e-030.13122.6353e-020.1113image
ENSG00000204054.10,LINC00963LGGEAG2.2480e-05-0.18375.5467e-05-0.17487.5406e-04-0.14651.3076e-05-0.1888image
chr9:129504107-129504436:+LUADEER1.7019e-030.13922.1432e-040.16385.7080e-040.15261.1984e-020.1116image
ENSG00000204054.10,LINC00963LUADEAG7.2788e-030.11881.5547e-040.16698.0154e-030.11741.2095e-020.1112image
chr9:129505935-129508836:+PAADEER3.8699e-030.21853.9893e-030.21781.2157e-020.19034.9989e-030.2125image
chr9:129505935-129508836:+SKCMEER1.1658e-06-0.22938.1625e-04-0.15902.6528e-06-0.22173.1551e-02-0.1025image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr9:129509997-129513099:+ACCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.6285e-02-0.4500image
ENSG00000204054.10,LINC00963ACCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.3731e-020.2455image
chr9:129504107-129504436:+ACCGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER4.0101e-030.3306image
chr9:129505935-129508836:+ACCGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.2933e-02-0.2678image
ENSG00000204054.10,LINC00963BLCAGSVA_HALLMARK_G2M_CHECKPOINTEAG6.0262e-050.1997image
chr9:129505935-129508836:+BLCAGSVA_HALLMARK_E2F_TARGETSEER3.0188e-040.1923image
chr9:129504107-129504436:+BLCAGSVA_HALLMARK_MTORC1_SIGNALINGEER6.3497e-050.2014image
chr9:129504107-129504436:+BRCAGSVA_HALLMARK_SPERMATOGENESISEER4.1474e-100.1888image
chr9:129502379-129503034:+BRCAGSVA_HALLMARK_MYC_TARGETS_V2EER1.5297e-050.2774image
chr9:129505935-129508836:+BRCAGSVA_HALLMARK_GLYCOLYSISEER1.3265e-080.1741image
ENSG00000204054.10,LINC00963BRCAGSVA_HALLMARK_G2M_CHECKPOINTEAG1.9130e-070.1576image
chr9:129509997-129513099:+BRCAGSVA_HALLMARK_MYC_TARGETS_V2EER3.9209e-03-0.1257image
ENSG00000204054.10,LINC00963CESCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.0176e-030.1770image
chr9:129505935-129508836:+CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.1998e-030.1913image
chr9:129509997-129513099:+CESCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER9.8098e-030.3454image
ENSG00000204054.10,LINC00963CHOLGSVA_HALLMARK_COMPLEMENTEAG3.8836e-03-0.4756image
chr9:129505935-129508836:+CHOLGSVA_HALLMARK_MYOGENESISEER5.4826e-03-0.4796image
chr9:129504107-129504436:+CHOLGSVA_HALLMARK_COAGULATIONEER1.9358e-02-0.3935image
ENSG00000204054.10,LINC00963COADGSVA_HALLMARK_PEROXISOMEEAG8.6371e-03-0.1619image
chr9:129505935-129508836:+COADGSVA_HALLMARK_COAGULATIONEER1.4730e-020.1624image
chr9:129504107-129504436:+COADGSVA_HALLMARK_PEROXISOMEEER1.0969e-02-0.1575image
ENSG00000204054.10,LINC00963ESCAGSVA_HALLMARK_COAGULATIONEAG9.7452e-03-0.2032image
chr9:129505935-129508836:+GBMGSVA_HALLMARK_G2M_CHECKPOINTEER1.2364e-020.2038image
chr9:129509997-129513099:+GBMGSVA_HALLMARK_ANGIOGENESISEER1.5063e-030.2914image
ENSG00000204054.10,LINC00963GBMGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG1.6197e-03-0.2458image
ENSG00000204054.10,LINC00963HNSCGSVA_HALLMARK_MTORC1_SIGNALINGEAG2.8379e-050.1879image
chr9:129505935-129508836:+HNSCGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.5248e-03-0.1530image
chr9:129509997-129513099:+HNSCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER2.5842e-02-0.3764image
chr9:129504107-129504436:+HNSCGSVA_HALLMARK_MTORC1_SIGNALINGEER1.5722e-060.2173image
chr9:129505935-129508836:+KICHGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER6.4748e-03-0.3370image
chr9:129509997-129513099:+KICHGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.8515e-020.4077image
ENSG00000204054.10,LINC00963KICHGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.5792e-030.3678image
chr9:129505935-129508836:+KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.2832e-070.2532image
ENSG00000204054.10,LINC00963KIRCGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.1053e-030.1663image
chr9:129504107-129504436:+KIRCGSVA_HALLMARK_COMPLEMENTEER3.9221e-030.1472image
chr9:129504107-129504436:+KIRPGSVA_HALLMARK_GLYCOLYSISEER4.2110e-040.2072image
ENSG00000204054.10,LINC00963KIRPGSVA_HALLMARK_GLYCOLYSISEAG1.3135e-030.1884image
chr9:129505935-129508836:+KIRPGSVA_HALLMARK_MYC_TARGETS_V1EER6.5176e-030.1608image
chr9:129509997-129513099:+KIRPGSVA_HALLMARK_NOTCH_SIGNALINGEER1.6525e-02-0.2380image
chr9:129504107-129504436:+LAMLGSVA_HALLMARK_G2M_CHECKPOINTEER1.1452e-030.3117image
ENSG00000204054.10,LINC00963LAMLGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.1049e-02-0.2415image
ENSG00000204054.10,LINC00963LGGGSVA_HALLMARK_UV_RESPONSE_UPEAG2.0875e-09-0.2574image
chr9:129505935-129508836:+LGGGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER4.5317e-03-0.1271image
chr9:129509997-129513099:+LGGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.7788e-02-0.1137image
chr9:129504107-129504436:+LGGGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.3697e-06-0.2093image
chr9:129509997-129513099:+LIHCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.7254e-030.3429image
ENSG00000204054.10,LINC00963LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.4683e-090.3074image
chr9:129505935-129508836:+LIHCGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.1717e-070.2666image
ENSG00000204054.10,LINC00963LUADGSVA_HALLMARK_PROTEIN_SECRETIONEAG2.1285e-070.2275image
chr9:129505935-129508836:+LUADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER4.9088e-080.2468image
chr9:129509997-129513099:+LUADGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.5333e-020.2182image
chr9:129504107-129504436:+LUADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER1.0093e-060.2154image
chr9:129505935-129508836:+LUSCGSVA_HALLMARK_KRAS_SIGNALING_DNEER4.0925e-03-0.1347image
ENSG00000204054.10,LINC00963LUSCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG5.2767e-030.1260image
chr9:129509997-129513099:+LUSCGSVA_HALLMARK_COMPLEMENTEER4.2782e-050.4262image
chr9:129504107-129504436:+LUSCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER1.1296e-040.1744image
chr9:129504107-129504436:+MESOGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER5.4440e-03-0.3061image
ENSG00000204054.10,LINC00963MESOGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.8955e-03-0.3380image
chr9:129505935-129508836:+MESOGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER1.9612e-02-0.2589image
chr9:129502379-129503034:+OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.7912e-050.2923image
chr9:129505935-129508836:+OVGSVA_HALLMARK_MYC_TARGETS_V1EER1.3467e-030.1890image
ENSG00000204054.10,LINC00963OVGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG2.6125e-03-0.1755image
chr9:129491964-129493107:+OVGSVA_HALLMARK_MYC_TARGETS_V2EER3.2681e-030.6242image
chr9:129509997-129513099:+OVGSVA_HALLMARK_UV_RESPONSE_UPEER2.7459e-060.3035image
ENSG00000204054.10,LINC00963PAADGSVA_HALLMARK_GLYCOLYSISEAG4.0536e-050.3034image
chr9:129504107-129504436:+PAADGSVA_HALLMARK_GLYCOLYSISEER2.4297e-050.3124image
chr9:129505935-129508836:+PAADGSVA_HALLMARK_GLYCOLYSISEER2.9333e-040.2721image
chr9:129505935-129508836:+PCPGGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.9632e-02-0.2021image
ENSG00000204054.10,LINC00963PCPGGSVA_HALLMARK_APICAL_JUNCTIONEAG9.3838e-03-0.1953image
chr9:129504107-129504436:+PCPGGSVA_HALLMARK_MYC_TARGETS_V2EER2.6053e-02-0.1707image
chr9:129504107-129504436:+PRADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.6232e-040.1682image
ENSG00000204054.10,LINC00963PRADGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG3.6173e-04-0.1590image
chr9:129505935-129508836:+PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5257e-040.1694image
chr9:129509997-129513099:+PRADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.7674e-030.1571image
chr9:129505935-129508836:+READGSVA_HALLMARK_DNA_REPAIREER8.4295e-03-0.2891image
chr9:129509997-129513099:+SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.1296e-02-0.1535image
ENSG00000204054.10,LINC00963SARCGSVA_HALLMARK_KRAS_SIGNALING_UPEAG7.2994e-03-0.1670image
chr9:129505935-129508836:+SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.3285e-030.2015image
chr9:129505935-129508836:+SKCMGSVA_HALLMARK_GLYCOLYSISEER3.9110e-04-0.1683image
ENSG00000204054.10,LINC00963SKCMGSVA_HALLMARK_COAGULATIONEAG7.5095e-04-0.1561image
chr9:129509997-129513099:+SKCMGSVA_HALLMARK_G2M_CHECKPOINTEER1.0762e-020.2648image
chr9:129504107-129504436:+SKCMGSVA_HALLMARK_MYC_TARGETS_V1EER5.2143e-040.1615image
ENSG00000204054.10,LINC00963STADGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.1415e-02-0.1323image
chr9:129502379-129503034:+STADGSVA_HALLMARK_FATTY_ACID_METABOLISMEER1.5542e-040.2724image
chr9:129509997-129513099:+STADGSVA_HALLMARK_MYC_TARGETS_V2EER2.6875e-030.2410image
chr9:129504107-129504436:+TGCTGSVA_HALLMARK_MYC_TARGETS_V2EER2.2131e-040.3666image
ENSG00000204054.10,LINC00963TGCTGSVA_HALLMARK_MYOGENESISEAG1.1945e-05-0.4149image
chr9:129505935-129508836:+TGCTGSVA_HALLMARK_MYC_TARGETS_V2EER6.7890e-030.3142image
chr9:129505935-129508836:+THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.5345e-080.2489image
chr9:129509997-129513099:+THCAGSVA_HALLMARK_DNA_REPAIREER5.0398e-04-0.1812image
chr9:129504107-129504436:+THCAGSVA_HALLMARK_E2F_TARGETSEER1.2624e-060.2139image
ENSG00000204054.10,LINC00963THCAGSVA_HALLMARK_E2F_TARGETSEAG9.6254e-060.1957image
ENSG00000204054.10,LINC00963THYMGSVA_HALLMARK_MYOGENESISEAG5.4283e-03-0.2544image
chr9:129505935-129508836:+THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER2.6991e-03-0.2821image
chr9:129504107-129504436:+THYMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.0336e-02-0.2352image
chr9:129505935-129508836:+UCECGSVA_HALLMARK_PEROXISOMEEER2.1124e-03-0.2377image
chr9:129509997-129513099:+UCECGSVA_HALLMARK_P53_PATHWAYEER8.3287e-040.4454image
ENSG00000204054.10,LINC00963UCECGSVA_HALLMARK_BILE_ACID_METABOLISMEAG1.7458e-02-0.1805image
chr9:129504107-129504436:+UCSGSVA_HALLMARK_KRAS_SIGNALING_DNEER4.8729e-02-0.2670image
chr9:129505935-129508836:+UVMGSVA_HALLMARK_PROTEIN_SECRETIONEER1.6006e-04-0.5445image
ENSG00000204054.10,LINC00963UVMGSVA_HALLMARK_KRAS_SIGNALING_UPEAG6.1292e-03-0.3365image


Top

7. Enriched editing regions and drugs for LINC00963


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr9:129509997-129513099:+ACCJNK.Inhibitor.VIIIEER1.6265e-02-0.4500image
ENSG00000204054.10,LINC00963ACCAICAREAG8.3222e-03-0.3026image
chr9:129504107-129504436:+ACCAICAREER2.0033e-02-0.2699image
chr9:129505935-129508836:+ACCJNK.Inhibitor.VIIIEER9.3210e-03-0.3044image
ENSG00000204054.10,LINC00963BLCAJNK.Inhibitor.VIIIEAG1.5837e-07-0.2591image
chr9:129505935-129508836:+BLCAKU.55933EER1.8566e-05-0.2270image
chr9:129504107-129504436:+BLCAJNK.Inhibitor.VIIIEER8.6067e-06-0.2235image
chr9:129504107-129504436:+BRCAAZD6244EER2.1971e-050.1289image
chr9:129502379-129503034:+BRCAGW843682XEER1.8778e-04-0.2408image
chr9:129505935-129508836:+BRCACMKEER1.1990e-05-0.1347image
ENSG00000204054.10,LINC00963BRCAAMG.706EAG6.2078e-040.1039image
ENSG00000204054.10,LINC00963CESCCI.1040EAG4.7525e-03-0.1621image
chr9:129505935-129508836:+CESCAKT.inhibitor.VIIIEER3.0619e-030.1751image
chr9:129509997-129513099:+CESCAxitinibEER2.9157e-02-0.2944image
ENSG00000204054.10,LINC00963CHOLBIBW2992EAG1.6458e-02-0.4027image
chr9:129505935-129508836:+CHOLDocetaxelEER3.3403e-030.5030image
chr9:129504107-129504436:+CHOLCGP.082996EER1.1346e-02-0.4230image
ENSG00000204054.10,LINC00963COADLapatinibEAG2.9402e-020.1348image
chr9:129505935-129508836:+COADCisplatinEER1.5840e-02-0.1607image
chr9:129504107-129504436:+COADABT.888EER8.9797e-03-0.1617image
chr9:129504107-129504436:+DLBCA.443654EER1.0578e-020.3817image
ENSG00000204054.10,LINC00963DLBCAxitinibEAG3.3497e-03-0.4327image
chr9:129505935-129508836:+DLBCA.443654EER3.7066e-03-0.5586image
chr9:129509997-129513099:+ESCAAICAREER4.6323e-03-0.2881image
chr9:129502379-129503034:+ESCAAS601245EER5.6256e-050.3759image
ENSG00000204054.10,LINC00963ESCABIRB.0796EAG3.9686e-04-0.2759image
chr9:129505935-129508836:+ESCABleomycinEER2.7990e-02-0.1760image
chr9:129505935-129508836:+GBMEtoposideEER2.7924e-02-0.1795image
chr9:129509997-129513099:+GBMBMS.708163EER1.0713e-02-0.2361image
ENSG00000204054.10,LINC00963GBMAZD6482EAG5.3000e-03-0.2181image
ENSG00000204054.10,LINC00963HNSCEHT.1864EAG2.1277e-060.2123image
chr9:129505935-129508836:+HNSCGefitinibEER2.6101e-05-0.2039image
chr9:129504107-129504436:+HNSCEHT.1864EER4.5100e-050.1853image
chr9:129505935-129508836:+KICHBicalutamideEER2.8896e-020.2733image
ENSG00000204054.10,LINC00963KICHCCT018159EAG2.6203e-03-0.3672image
chr9:129505935-129508836:+KIRCGDC.0449EER6.3625e-08-0.2773image
ENSG00000204054.10,LINC00963KIRCCisplatinEAG3.1670e-05-0.2112image
chr9:129509997-129513099:+KIRCBIRB.0796EER1.2557e-02-0.1813image
chr9:129504107-129504436:+KIRCCisplatinEER3.2142e-03-0.1504image
chr9:129504107-129504436:+KIRPAUY922EER3.6040e-030.1716image
ENSG00000204054.10,LINC00963KIRPAUY922EAG3.5700e-050.2410image
chr9:129505935-129508836:+KIRPAS601245EER1.6249e-050.2523image
chr9:129509997-129513099:+KIRPErlotinibEER4.5412e-030.2802image
ENSG00000204054.10,LINC00963LAMLCMKEAG2.1979e-02-0.2183image
ENSG00000204054.10,LINC00963LGGCMKEAG5.3779e-080.2344image
chr9:129505935-129508836:+LGGCMKEER6.9670e-050.1774image
chr9:129509997-129513099:+LGGBI.D1870EER7.8935e-030.1274image
chr9:129504107-129504436:+LGGCMKEER2.7273e-040.1585image
chr9:129509997-129513099:+LIHCLapatinibEER2.5463e-030.3350image
ENSG00000204054.10,LINC00963LIHCAICAREAG4.2508e-09-0.2990image
chr9:129505935-129508836:+LIHCBleomycinEER2.2488e-090.3085image
ENSG00000204054.10,LINC00963LUADAS601245EAG5.1075e-050.1785image
chr9:129505935-129508836:+LUADGemcitabineEER4.4392e-06-0.2086image
chr9:129509997-129513099:+LUADAxitinibEER5.6310e-04-0.3066image
chr9:129504107-129504436:+LUADAP.24534EER3.1907e-040.1594image
chr9:129505935-129508836:+LUSCAS601245EER4.4303e-050.1906image
ENSG00000204054.10,LINC00963LUSCCMKEAG4.5516e-05-0.1833image
chr9:129509997-129513099:+LUSCAS601245EER4.1178e-04-0.3726image
chr9:129504107-129504436:+LUSCAS601245EER3.8685e-040.1605image
chr9:129509997-129513099:+MESOCCT018159EER1.9115e-020.3602image
chr9:129504107-129504436:+MESOIPA.3EER6.6539e-03-0.2992image
ENSG00000204054.10,LINC00963MESODoxorubicinEAG2.3372e-03-0.3316image
chr9:129505935-129508836:+MESOBleomycinEER5.9407e-03-0.3032image
chr9:129502379-129503034:+OVMG.132EER2.3284e-06-0.3276image
chr9:129505935-129508836:+OVAS601245EER2.2733e-060.2758image
ENSG00000204054.10,LINC00963OVBleomycinEAG4.1565e-06-0.2657image
chr9:129491964-129493107:+OVGSK.650394EER1.4075e-02-0.5396image
chr9:129509997-129513099:+OVA.770041EER1.3547e-07-0.3391image
ENSG00000204054.10,LINC00963PAADAZD6244EAG3.7177e-05-0.3048image
chr9:129504107-129504436:+PAADAZD6482EER7.4584e-050.2999image
chr9:129505935-129508836:+PAADGefitinibEER1.7642e-03-0.2368image
chr9:129505935-129508836:+PCPGAZD7762EER3.4500e-030.2519image
ENSG00000204054.10,LINC00963PCPGCHIR.99021EAG5.7491e-030.2074image
chr9:129504107-129504436:+PCPGGSK269962AEER1.0283e-020.1963image
chr9:129504107-129504436:+PRADMethotrexateEER1.4800e-06-0.2144image
ENSG00000204054.10,LINC00963PRADAZD.2281EAG2.2852e-07-0.2296image
chr9:129505935-129508836:+PRADCMKEER6.6261e-07-0.2213image
chr9:129509997-129513099:+PRADAZD.0530EER2.8133e-03-0.1739image
chr9:129505935-129508836:+READGSK.650394EER1.0419e-020.2815image
chr9:129504107-129504436:+READCMKEER3.4310e-020.2186image
chr9:129509997-129513099:+SARCCCT018159EER1.9664e-020.1752image
ENSG00000204054.10,LINC00963SARCCEP.701EAG2.3659e-030.1888image
chr9:129505935-129508836:+SARCCMKEER1.0488e-030.2057image
chr9:129505935-129508836:+SKCMCMKEER1.6873e-020.1139image
ENSG00000204054.10,LINC00963SKCMKIN001.135EAG6.1081e-040.1587image
chr9:129509997-129513099:+SKCMCGP.082996EER3.9047e-030.2981image
chr9:129504107-129504436:+SKCMDoxorubicinEER6.5825e-05-0.1854image
ENSG00000204054.10,LINC00963STADBMS.708163EAG2.5253e-050.2186image
chr9:129502379-129503034:+STADMetforminEER5.9291e-04-0.2482image
chr9:129505935-129508836:+STADBleomycinEER1.3553e-03-0.1736image
chr9:129491964-129493107:+STADLFM.A13EER3.2533e-020.3730image
chr9:129509997-129513099:+STADCCT007093EER2.0020e-040.2963image
chr9:129504107-129504436:+TGCTBIBW2992EER7.1696e-05-0.3920image
ENSG00000204054.10,LINC00963TGCTCGP.60474EAG1.0864e-050.4166image
chr9:129505935-129508836:+TGCTMidostaurinEER3.1138e-030.3414image
chr9:129505935-129508836:+THCACI.1040EER2.2109e-11-0.2925image
chr9:129509997-129513099:+THCABMS.708163EER2.1100e-07-0.2676image
chr9:129504107-129504436:+THCAAICAREER4.5422e-05-0.1806image
ENSG00000204054.10,LINC00963THCACI.1040EAG4.4439e-06-0.2028image
ENSG00000204054.10,LINC00963THYMFTI.277EAG5.5559e-030.2538image
chr9:129505935-129508836:+THYMJW.7.52.1EER5.3519e-07-0.4547image
chr9:129509997-129513099:+THYMElesclomolEER3.0587e-030.3618image
chr9:129504107-129504436:+THYMGefitinibEER3.5876e-04-0.3231image
chr9:129505935-129508836:+UCECBI.2536EER5.7622e-04-0.2652image
ENSG00000204054.10,LINC00963UCECBryostatin.1EAG3.0597e-030.2239image
ENSG00000204054.10,LINC00963UCSMetforminEAG3.5173e-02-0.2847image
chr9:129504107-129504436:+UCSCMKEER2.5798e-040.4738image
chr9:129505935-129508836:+UCSElesclomolEER4.0384e-02-0.2852image
chr9:129505935-129508836:+UVMBMS.708163EER4.6108e-030.4239image
ENSG00000204054.10,LINC00963UVMABT.263EAG1.1966e-020.3100image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType